eGFR and GLP-1 Kidney Outcomes Explained: What the Evidence Actually Says
Published:
·Last verified: May 19, 2026.·Reviewed quarterly against FDA labels and primary trial sourcesThe part most explanations skip:
These drugs are not simply “good for kidneys” or “bad for kidneys.” The truth depends on who you are, what your labs look like, and which drug you’re talking about. In adults with type 2 diabetes and CKD, once-weekly semaglutide 1 mg (Ozempic injection) lowered the risk of major kidney and cardiovascular-death events by 24% in the FLOW trial and slowed the yearly eGFR decline rate by 1.16 mL/min/1.73 m² per year. That is not the same as reversing kidney damage — and it does not apply to everyone.
eGFR and GLP-1 kidney outcomes explained: where do you fit?
| Your situation | What the evidence shows | What to ask next |
|---|---|---|
| AType 2 diabetes + CKD | Strongest evidence. Ozempic injection 1 mg is FDA-approved to lower the risk of worsening kidney disease, kidney failure, and CV death. | Ask whether your eGFR, UACR, and overall risk profile fit the FLOW trial criteria — and which kidney-protective drugs you should already be on. |
| BObesity + heart disease, no diabetes | Promising. SELECT showed kidney benefit with Wegovy 2.4 mg, but no FDA kidney approval. | Ask whether SELECT-like evidence applies to your CV risk profile and whether kidney protection should be a primary or secondary goal. |
| ?Low eGFR but no UACR result | Incomplete picture. eGFR alone is not enough to match you to trial evidence. | Request a UACR test and ask to review your eGFR trend over time, not just one reading. |
| !eGFR dropped after starting a GLP-1 | Could be normal, could be a warning. A small early dip is expected. A bigger drop with vomiting or dehydration is not. | Call your clinician before changing anything — especially if you have been sick or cannot keep fluids down. |
| DStage 4 CKD, dialysis, or transplant | More individualized. Direct evidence in advanced CKD is thinner. | Loop in a nephrologist. The decision is not a general one. |
Not sure which evidence bucket fits your situation?
Use our free Evidence Checker below to map your eGFR, UACR, and diabetes status to the published trial evidence — then get tailored questions for your clinician appointment.
Go to Evidence Checker ↓What we actually verified for this page
FDA labels: We pulled the current prescribing information for Ozempic (injection and tablets), Wegovy (injection 2.4 mg, Wegovy HD injection 7.2 mg, and Wegovy tablets), Rybelsus, Trulicity, Victoza, Saxenda, Mounjaro, Zepbound, Byetta, Bydureon BCise, Adlyxin, and Foundayo (orforglipron) from Drugs@FDA. Every "approved for X" claim on this page is from a current US label as of May 19, 2026.
Primary trial papers: All hazard ratios, confidence intervals, and eGFR slope numbers came from original publications: FLOW (Perkovic et al., NEJM 2024), SELECT kidney analysis (Colhoun et al., Nature Medicine 2024), SURPASS-4 (Heerspink et al., Lancet Diabetes Endocrinol 2022), AMPLITUDE-O (Gerstein et al., NEJM 2021), SOUL (McGuire et al., NEJM 2025), the non-diabetic CKD semaglutide trial (Heerspink et al., Nature Medicine October 2024), and others listed in our sources.
Guidelines: Recommendations about layering treatments come from the KDIGO 2024 CKD Guideline and the ADA Standards of Care 2026 (Section 11: CKD and Risk Management).
Editorial vs. factual: Where we say "this is the strongest evidence" or "this matters more than that," we are giving our read. Where we say "the FDA approved" or "the trial showed," it is a fact from the source.
Nothing on this page is medical advice for you specifically. It is research synthesis, written so you can have a smarter conversation with the person who actually knows your kidneys.
What is eGFR, and why one number doesn’t tell the whole story
How eGFR is calculated
The National Kidney Foundation recommends that clinical labs use the race-free CKD-EPI 2021 equation to estimate eGFR from creatinine. Some labs still report older equations, so check what yours uses if you are comparing across labs. Some labs also offer cystatin C-based eGFR, which does not depend on muscle mass — useful for people who have lost significant weight rapidly on a GLP-1.
The CKD stages, in plain English
| eGFR (mL/min/1.73 m²) | Stage | Plain language |
|---|---|---|
| 90 or higher | G1 (with other kidney damage signs) | Normal filtering, but watch for albumin in urine |
| 60–89 | G2 (with other kidney damage signs) | Mild drop; not CKD unless other markers are present |
| 45–59 | G3a | Moderate drop. Monitoring matters. |
| 30–44 | G3b | More moderate. Most CKD medication decisions land here. |
| 15–29 | G4 | Severe. Pre-dialysis territory. Specialist care is standard. |
| Below 15 | G5 | Kidney failure. Dialysis or transplant range. |
KDIGO 2024 also says that in people with CKD, an eGFR change of more than 20% on a follow-up test exceeds expected day-to-day variability and warrants evaluation. A GFR reduction of more than 30% on subsequent testing also warrants evaluation for people starting hemodynamically active therapies (KDIGO 2024 CKD Guideline).
Why your eGFR can move without your kidneys changing
Dehydration
Less fluid in your blood means less gets filtered. eGFR drops.
Rapid weight loss
Less muscle means less creatinine. eGFR can look higher without your kidneys actually improving. This matters for GLP-1 users.
Recent protein-heavy meal or hard workout
Creatinine spikes temporarily.
Acute illness, NSAIDs, contrast scans, diuretic changes
All of these can move the number.
Time of day and lab variability
Small but real.
Why UACR matters as much as eGFR (and most people don’t know this)
UACR stands for urine albumin-to-creatinine ratio. It measures whether your kidneys are leaking protein. Two people can have the same eGFR of 55 but completely different kidney risk — the one with a UACR of 600 mg/g is in a much worse position than the one with a UACR of 12.
The FLOW trial did not enroll people just by eGFR. It used eGFR plus UACR thresholds to define CKD. If your doctor has not ordered a UACR, ask for one. It is a simple urine test and it changes the picture significantly.
Does my lab profile match the FLOW trial?
FLOW enrolled adults with type 2 diabetes who met one of these two combinations (Perkovic et al., NEJM 2024):
| Your eGFR (mL/min/1.73 m²) | Your UACR (mg/g) | Match? |
|---|---|---|
| 50–75 | 300–5,000 | ✅ FLOW-like |
| 25 to <50 | 100–5,000 | ✅ FLOW-like |
| 45–59 with no UACR result | — | Incomplete; ask for UACR |
| 60–89 with UACR ≥30 | — | Possible CKD risk; clinical context needed |
| Below 25, or above 75, or no T2D | — | Outside FLOW criteria; individual decision |
Does Ozempic improve eGFR, or just slow its decline?
Slowing decline
The drop is smaller per year than it would have been. Over time, that adds up to years of preserved kidney function and fewer people reaching dialysis or transplant.
Improving eGFR
The number actually goes up. If this happens after starting a GLP-1, weight loss and a healthier metabolic state can explain part of it — but rapid weight loss also drops creatinine because you have less muscle, which can make creatinine-based eGFR look better than actual function. That is where cystatin C helps.
How GLP-1 drugs affect your kidneys — the mechanism in plain English
Indirect mechanisms (drug effects on the rest of you that help your kidneys)
- ·Lower A1c means less sugar damage to blood vessels in the kidney
- ·Lower blood pressure means less mechanical strain on glomeruli (kidney filters)
- ·Lower weight means less obesity-related kidney stress
- ·Lower albumin leak — UACR fell 20–40% across major trials; in the non-diabetic obesity + CKD trial (Heerspink et al., Nature Medicine Oct 2024), semaglutide 2.4 mg reduced UACR by 52.1% at 24 weeks vs. placebo
Proposed direct mechanisms (what the drug may do to kidney cells directly)
- ·Lowers intraglomerular pressure — in diabetes and obesity, the tiny filters work too hard; GLP-1s appear to ease that pressure
- ·Reduces inflammation markers — kidney inflammation markers dropped meaningfully in the non-diabetic obesity + CKD trial
- ·Reduces fat around the kidneys — less metabolic stress on the organ
- ·Promotes sodium excretion (natriuresis), which lowers pressure inside the kidney
The early eGFR dip with GLP-1 drugs: what it is and how to read it
Two trials, two pieces of the picture
| Trial | What it measured | Time frame | Result |
|---|---|---|---|
| SELECT acute eGFR substudy (semaglutide 2.4 mg, no diabetes, ~34% with frequent draws) | Early eGFR trajectory | Weeks 0–20 | Semaglutide group had a larger early dip; nadir around week 8; similar to placebo by week 20 |
| FLOW (semaglutide 1 mg, T2D + CKD) | Long-term annual eGFR slope | 3.4-year median follow-up | Semaglutide slowed eGFR decline by 1.16 mL/min/1.73 m²/year vs. placebo |
Why your kidneys “calm down” instead of getting damaged
In diabetes and obesity, the kidney's filters often work in overdrive — what doctors call hyperfiltration. On paper this can look fine (eGFR may even be elevated), but the overwork wears the filters out over years. Hemodynamically active drugs (ACE inhibitors, ARBs, SGLT2 inhibitors, and GLP-1s) lower that internal pressure. eGFR drops a little because the kidney is working less hard per filter — and that is the trade-off that produces long-term protection.
The SGLT2 inhibitor parallel: In the DAPA-HF trial, people on dapagliflozin who had a larger early eGFR dip ended up with better long-term outcomes than those who did not dip (Adamson et al., Circulation 2022). The dip was not damage — it was the kidney accepting a healthier workload. The pattern with GLP-1s appears similar.
When the dip is actually concerning (red flags)
A small early dip is expected. A bigger one is not. Call your doctor — do not wait for the next scheduled visit — if you see any of these:
- ⚠A drop greater than 30% from your baseline that does not recover
- ⚠Persistent nausea, vomiting, or diarrhea you cannot stop
- ⚠Very little urine output
- ⚠Swelling, confusion, or lightheadedness when standing
- ⚠Rising creatinine or low sodium on labs
These are signs of acute kidney injury (sudden kidney damage), which is different from the expected dip. It is almost always tied to dehydration from GI side effects and is often preventable — but the FDA label warning exists because serious cases can occur (FDA Ozempic label, 2025).
GLP-1 kidney outcomes trials, drug by drug: the full evidence matrix
| Trial (year) | Drug + dose | Population | N | Follow-up | Hazard ratio (95% CI) | eGFR slope vs comparator |
|---|---|---|---|---|---|---|
| FLOW (2024) | Semaglutide 1.0 mg SC weekly | T2D + CKD (eGFR 25–75 with UACR 100–5,000) | 3,533 | 3.4 yrs | 0.76 (0.66–0.88) — 24% RRR | +1.16 mL/min/1.73 m²/yr (slower decline) |
| SELECT kidney (2024) | Semaglutide 2.4 mg SC weekly | Overweight/obesity + CVD, no diabetes | 17,604 | 3.3 yrs | 0.78 (0.63–0.96) — 22% RRR | +0.75 mL/min overall; +2.19 if baseline eGFR <60 |
| SUSTAIN-6 + LEADER pooled (2022) | Semaglutide 0.5/1.0 mg + Liraglutide 1.8 mg | T2D + high CV risk | 12,637 | ~3 yrs each | Significant for ≥40% and ≥50% eGFR decline | Slowed eGFR decline, especially in baseline CKD subgroup |
| REWIND (2019) | Dulaglutide 1.5 mg SC weekly | T2D + CV risk factors | 9,901 | 5.4 yrs | 0.85 (0.77–0.93) for composite | Modest eGFR preservation |
| AWARD-7 (2018) | Dulaglutide 1.5 mg vs insulin glargine | T2D + moderate–severe CKD | 577 | 52 weeks | — | Preserved eGFR vs. glargine in stage 3–4 CKD |
| AMPLITUDE-O (2021) | Efpeglenatide 4–6 mg SC weekly | T2D + CV disease or CKD | 4,076 | 1.8 yrs | 0.68 (0.57–0.79) — 32% RRR | — |
| SURPASS-4 post-hoc (2022) | Tirzepatide 5/10/15 mg vs glargine | T2D + high CV risk | 1,995 analyzed | 85 weeks | 0.58 (0.43–0.80) | +2.2 mL/min/1.73 m²/yr |
| EXSCEL (2017) | Exenatide ER 2 mg weekly | T2D ± CV disease | 14,752 | 3.2 yrs | No significant overall effect | Favorable in albuminuria subgroup only |
| SOUL (2025) | Oral semaglutide 14 mg daily | T2D + ASCVD and/or CKD | 9,650 | 47.5 months | Numerically lower, not statistically significant for kidney composite; MACE HR 0.86 | — |
| Semaglutide obesity + non-diabetic CKD (Oct 2024) | Semaglutide 2.4 mg | Overweight/obesity + CKD, no diabetes | 101 | 24 weeks | −52.1% UACR vs. placebo | Short trial; albuminuria endpoint, not hard kidney outcomes |
Every number was pulled from the original publication. Green row = dedicated kidney trial with FDA-approved indication.
The headline trial: FLOW, in plain terms
If you remember one trial from this page, make it FLOW.
Population
3,533 adults with type 2 diabetes and CKD. Mean baseline eGFR 47. Most had moderate-to-advanced disease.
Drug
Once-weekly semaglutide 1 mg vs. placebo, on top of standard care that included an ACE inhibitor or ARB.
Main result
24% lower risk of the main outcome — kidney failure, kidney death, CV death, or a 50% drop in eGFR. HR 0.76 (95% CI 0.66–0.88); p = 0.0003.
Absolute terms
18.7% of semaglutide group had a primary outcome event vs. 23.2% of placebo. That is a 4.5 percentage point difference. Estimated NNT: about 20 to prevent one major event over three years.
Bonus findings
18% reduction in major cardiovascular events. 29% reduction in CV death. 20% reduction in death from any cause.
Safety
Serious adverse events were lower with semaglutide (49.6% vs. 53.8%). The trial was stopped early by its independent data monitoring committee because the benefit was so clear.
This is the trial the FDA built the Ozempic kidney indication on.
The class-extending trial: SELECT
SELECT was originally a cardiovascular trial. Its kidney analysis was prespecified but secondary. 17,604 adults with overweight or obesity and established cardiovascular disease, without type 2 diabetes. Drug: Semaglutide 2.4 mg (Wegovy injection) vs. placebo. Kidney result: 22% lower risk of the kidney composite (HR 0.78); larger benefit in those starting with eGFR below 60.
The evidence tier framework: how strong is the kidney evidence for your situation?
Tier A — Strongest: FDA-approved indication
Adults with type 2 diabetes and CKD considering semaglutide 1 mg (Ozempic injection). The FDA label (updated January 28, 2025) specifically approves Ozempic injection 1 mg to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in this exact population. This is the only Tier A bucket in the GLP-1 class right now.
Tier B — Strong (randomized trial data, no FDA kidney indication)
Includes: (1) Adults with overweight/obesity and cardiovascular disease, no diabetes, considering semaglutide 2.4 mg (Wegovy injection) — SELECT's kidney analysis showed 22% lower kidney composite risk, but Wegovy has no FDA kidney indication. (2) Adults with T2D and high CV risk considering tirzepatide — SURPASS-4 showed a 42% lower composite kidney event risk vs. insulin glargine in a post-hoc analysis, but tirzepatide has no FDA kidney indication. (3) Adults with obesity and non-diabetic CKD considering semaglutide 2.4 mg — the 24-week trial showed 52.1% UACR reduction, but short follow-up and a surrogate endpoint.
Tier C — Supportive (class-level signals, no dedicated kidney trial)
Liraglutide, dulaglutide, and oral semaglutide for kidney protection. All three show class-level kidney signals (slower eGFR decline, less albuminuria) in cardiovascular outcomes trials. None has a dedicated kidney trial or kidney indication.
Tier D — Insufficient direct evidence
Use in eGFR below 15 or on dialysis — almost no trial enrolled these patients. Also: GLP-1 use for primary CKD prevention in people without diabetes, obesity, or CV disease — no trial has been designed to test this.
Which GLP-1 is FDA-approved for kidney disease (and which aren’t)
| Drug (brand) | Type 2 diabetes | CV risk reduction | Weight management | Kidney indication | Other |
|---|---|---|---|---|---|
| Semaglutide injection — Ozempic 0.5/1/2 mg | ✅ (2017) | ✅ (2020, in T2D + CVD) | ❌ (separate brand) | ✅ Jan 28, 2025 — T2D + CKD; kidney-risk dose 1 mg weekly | — |
| Semaglutide tablets — Ozempic tablets | ✅ | ✅ in high-risk T2D | ❌ | ❌ (no CKD indication for tablet form) | — |
| Semaglutide oral — Rybelsus | ✅ | ✅ MACE risk reduction in high-risk T2D (label updated 2025) | ❌ | ❌ | — |
| Semaglutide injection — Wegovy 2.4 mg | ❌ | ✅ (2024, in obesity + CVD) | ✅ (2021) | ❌ (kidney benefit in SELECT, no indication) | MASH with fibrosis (2025) |
| Semaglutide tablets — Wegovy tablets 25 mg | ❌ | ✅ in labeled use | ✅ (oral weight management) | ❌ | — |
| Semaglutide injection — Wegovy HD 7.2 mg | ❌ | ✅ in labeled use | ✅ (approved March 2026) | ❌ | — |
| Liraglutide — Victoza | ✅ | ✅ | ❌ (separate brand) | ❌ | — |
| Liraglutide — Saxenda | ❌ | ❌ | ✅ | ❌ | — |
| Dulaglutide — Trulicity | ✅ | ✅ | ❌ | ❌ | — |
| Tirzepatide — Mounjaro | ✅ | Under study | ❌ (separate brand) | ❌ | — |
| Tirzepatide — Zepbound | ❌ | ❌ | ✅; also sleep apnea in obesity (2024) | ❌ | — |
| Exenatide IR — Byetta | ✅ | ❌ | ❌ | ❌ | Use caution in moderate renal impairment; not recommended in severe renal impairment or ESRD |
| Exenatide ER — Bydureon BCise | ✅ | ❌ | ❌ | ❌ | Not recommended for eGFR <45 or ESRD |
| Lixisenatide — Adlyxin | ✅ | ❌ | ❌ | ❌ | Limited experience in severe renal impairment; not recommended in ESRD/eGFR <15 |
| Orforglipron — Foundayo (Lilly, approved April 1, 2026) | ✅ (oral, once-daily, non-peptide GLP-1) | Under study | ❌ | ❌ | First oral non-peptide GLP-1 |
Sources: Current FDA prescribing information for each drug, verified May 19, 2026. We will update this table when any kidney indication changes.
Why “kidney benefit in a trial” does not equal “FDA-approved for kidney use”
Two things can both be true: (1) Wegovy injection's SELECT trial showed real kidney benefit in people with obesity and CVD. (2) Wegovy injection does not have an FDA-approved indication for kidney disease.
Insurance companies and prior authorization teams base coverage on the FDA-approved indication. If a clinician says “Ozempic injection is approved for your kidney disease,” that is accurate at the right dose and population. If a marketing page says a GLP-1 is “kidney-friendly,” that may reflect real trial data — but it is not the same as an FDA approval.
GLP-1 eligibility by eGFR: the practical thresholds
| eGFR band (mL/min/1.73 m²) | Semaglutide (Ozempic / Wegovy / Rybelsus) | Liraglutide | Dulaglutide | Tirzepatide | Exenatide IR (Byetta) | Exenatide ER (Bydureon BCise) | Lixisenatide (Adlyxin) |
|---|---|---|---|---|---|---|---|
| ≥60 | Usable | Usable | Usable | Usable | Usable | Usable | Usable |
| 45–59 (G3a) | Usable | Usable | Usable | Usable | Use caution | Usable | Usable; monitor |
| 30–44 (G3b) | Usable; Ozempic 1 mg has kidney indication in T2D + CKD | Usable | Usable | Usable | Use caution | Not recommended | Use caution; monitor |
| 15–29 (G4) | Usable; limited data; monitor closely | Usable; monitor | Usable; monitor | Limited data; monitor | Not recommended | Not recommended | Limited experience; close monitoring |
| <15 / ESRD / dialysis | Insufficient data; specialist call | Insufficient | Insufficient | No dosage adjustment per label; specialist call | Not recommended | Not recommended | Not recommended |
Sources: Current FDA prescribing information for each drug; KDIGO 2024 CKD Guideline. Reverified May 19, 2026.
What “usable” does not mean
“Usable” means the FDA label and major guidelines do not block you. It does not mean it is automatically the right choice. Dose escalation may need to go slower in low-eGFR patients, and GI side effects matter more because dehydration is more dangerous when your kidneys have less margin.
Layered therapy: GLP-1s add to other kidney-protective drugs
For adults with type 2 diabetes and CKD, KDIGO 2024 and ADA Standards of Care 2026 (Section 11) recommend foundational therapy with an ACE inhibitor or ARB (for blood pressure and protein in urine) plus an SGLT2 inhibitor (for kidney and CV protection), with a GLP-1 receptor agonist added for glycemic control and additional CV/kidney protection, and finerenone considered for patients with persistent albuminuria.
In FLOW, only 15.6% of participants were on an SGLT2 inhibitor at baseline (Perkovic et al., NEJM 2024). The additive benefit when both are used is still being defined, but current guidance is to use them together when appropriate.
Can GLP-1 drugs actually hurt kidneys? The dehydration and AKI question
How dehydration causes AKI
This is not the same as the slow, mild eGFR dip discussed earlier. The early dip is a small, expected adjustment. AKI is a sharp drop, usually with sick symptoms, that can require hospitalization in severe cases.
Red flags: when to call your doctor (do not wait and see)
Get medical attention promptly if you are on a GLP-1 and you have:
- ⚠Vomiting or diarrhea that will not stop — more than 24 hours, or you cannot keep liquids down
- ⚠Very little urine (much less than usual, or dark color)
- ⚠Dizziness or fainting when standing
- ⚠Confusion or new severe fatigue
- ⚠Severe abdominal pain
- ⚠A sudden eGFR drop greater than 30% on a lab draw
If you have CKD already, these symptoms are higher stakes. Do not wait for your next scheduled appointment.
The sick-day plan question
Most clinicians can give you a sick-day plan — a written guide for what to do if you are vomiting, have a fever, or cannot eat normally. It usually covers:
- ·Which medications to pause temporarily (sometimes diuretics or the SGLT2 inhibitor)
- ·How aggressively to hydrate
- ·When to call the office vs. go to urgent care vs. go to the ER
- ·When it is safe to restart pauseable medications
Ask for one. It is standard practice and it is how clinicians prevent AKI in vulnerable patients.
Other things that can drop your eGFR (and are not the GLP-1)
How GLP-1 drugs compare to SGLT2 inhibitors, ACE/ARBs, and finerenone
| Drug class | Main kidney role | Strongest evidence | How it works |
|---|---|---|---|
| ACE inhibitors / ARBs | First-line for albuminuria + blood pressure | RENAAL, IDNT (irbesartan), and others | Lowers pressure in kidney filters; reduces protein leak |
| SGLT2 inhibitors | Broadest kidney protection across diabetic and non-diabetic CKD | DAPA-CKD, EMPA-KIDNEY, CREDENCE | Lowers intraglomerular pressure differently; major eGFR slope benefits |
| GLP-1 receptor agonists | Layered in T2D + CKD; also reduces CV risk | FLOW (semaglutide); secondary signals across class | Reduces inflammation, weight, BP, hyperfiltration |
| Finerenone | Adds protection in T2D + CKD with persistent albuminuria | FIDELIO-DKD, FIGARO-DKD | Non-steroidal mineralocorticoid receptor blocker |
GLP-1s and SGLT2 inhibitors work through different kidney mechanisms. They are complementary, not interchangeable. Current guidance supports using them together when appropriate, individual contraindications and monitoring requirements permitting.
If your eGFR dropped on a GLP-1: how to read what it means
Pattern 1: Small dip (10–20%), no symptoms, stabilizes by week 12–24
This is the expected hemodynamic adjustment — the same kind doctors see with ACE inhibitors and SGLT2 inhibitors. Generally, you stay the course unless your clinician sees something else in your overall picture.
Pattern 2: Bigger dip (>30%), no obvious illness
Less common. Worth investigating other contributors — new NSAID, recent contrast scan, undetected dehydration, recent medication change. Your doctor will likely repeat labs and review your meds.
Pattern 3: Sharp drop with vomiting, diarrhea, low urine output, or dizziness
This is the acute kidney injury picture. It needs prompt medical attention. The GLP-1 may need to be paused; IV fluids may be needed; other meds may need temporary adjustment.
When to ask for cystatin C
If you have lost significant weight on a GLP-1 — roughly 10% of your body weight or more — your creatinine may be lower simply because you have less muscle. That can make eGFR look better than your kidneys actually warrant. Cystatin C-based eGFR does not depend on muscle mass and gives a cleaner reading in that situation. Most labs offer it as an add-on. Ask your clinician whether it is worth checking.
The lab trend table to build before your appointment
Fill this out and bring it to your next visit. A clinician looking at this table can answer your question in 30 seconds. Without it, they are guessing from one or two data points.
| Date | eGFR | Creatinine | UACR | Drug + dose | Days since start or dose change | Weight | Notable symptoms | Other med changes |
|---|---|---|---|---|---|---|---|---|
Use our free Evidence Checker first
Enter your lab values and situation to find out which evidence tier applies to you and get tailored questions for your clinician.
eGFR + GLP-1 Evidence Checker
Enter your lab values and situation to see which evidence tier applies and get tailored questions for your clinician. This is not a diagnostic tool. It maps inputs to published evidence — not medical advice.
eGFR and diabetes status are required
Questions to ask your doctor
If you have type 2 diabetes and CKD
- 1“Does my eGFR and UACR fit the FLOW trial criteria?”
- 2“Should we consider Ozempic injection 1 mg specifically for kidney protection?”
- 3“Am I already on an ACE inhibitor or ARB? Should an SGLT2 inhibitor be added or optimized?”
- 4“How often will we check eGFR, creatinine, potassium, and UACR?”
- 5“What is my sick-day plan if I get the flu or food poisoning?”
If you have overweight or obesity and heart disease but not diabetes
- 1“Does the SELECT trial evidence apply to my risk profile?”
- 2“Would Wegovy primarily be for cardiovascular and weight goals, with kidney benefit as a secondary effect?”
- 3“What other kidney-protective steps should I be taking — blood pressure, weight, SGLT2 inhibitor if I have CKD?”
If your eGFR dropped after starting a GLP-1
- 1“Could dehydration, NSAID use, or recent illness explain this?”
- 2“Should we repeat labs in 1–2 weeks?”
- 3“Should we check cystatin C given my weight loss?”
- 4“Is this within the expected dip range or a real concern?”
- 5“Should I be on a sick-day plan going forward?”
If you have stage 4 CKD, dialysis, or transplant evaluation
- 1“Does the trial evidence apply to my CKD stage and underlying cause?”
- 2“Who coordinates this decision — primary care, endocrinology, nephrology, or all three?”
- 3“Are there nutrition or hydration concerns specific to my situation?”
- 4“Could weight loss affect my transplant candidacy?”
What is still unknown (the honest section)
- ?
Does the kidney benefit extend to people with obesity-related CKD without diabetes or CVD over the long term?
The 24-week trial showed strong albuminuria benefit (Heerspink et al., Nature Medicine October 2024). A longer trial with hard kidney outcomes is still needed.
- ?
Long-term (5+ year) outcomes?
Most trials reported 2–4 year follow-up. The lifetime trajectory is still being learned.
- ?
People with eGFR <25 or on dialysis?
Almost no trial data. Decisions here are individualized and specialist-led.
- ?
Oral semaglutide for kidney protection?
SOUL was numerically favorable but not statistically significant for the kidney composite. The injectable form has stronger evidence.
- ?
Tirzepatide's hard kidney outcomes?
A dedicated trial is the missing piece. Eli Lilly's program is active.
- ?
Orforglipron (Foundayo), approved April 2026?
First oral non-peptide GLP-1. Kidney outcomes data not yet available.
- ?
The right additive sequence?
Should you start a GLP-1 first and add an SGLT2 inhibitor later, or the reverse? Comparative trials are scarce.
We will update this page when each of these reads out. Quarterly review is on the calendar.
Frequently asked questions about eGFR and GLP-1 kidney outcomes
Does Ozempic improve eGFR?
In the FLOW trial, semaglutide did not improve eGFR in the sense of reversing kidney damage. It slowed the rate of eGFR decline by 1.16 mL/min/1.73 m² per year compared with placebo and reduced major kidney and cardiovascular-death events by 24% in adults with type 2 diabetes and CKD (Perkovic et al., NEJM 2024). Over 5 years, that translates to about 5.8 mL/min/1.73 m² of preserved kidney function.
Is Ozempic approved for kidney disease?
Yes, but only in a specific population. On January 28, 2025, the FDA approved Ozempic injection (semaglutide 1 mg) to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD. It is the first and currently only GLP-1 receptor agonist with an FDA kidney indication.
Why did my eGFR drop after starting Ozempic?
A small drop in the first 4 to 12 weeks is generally expected and not a sign of damage. It reflects reduced internal pressure in the kidney filters, a hemodynamic adjustment similar to what happens with ACE inhibitors and SGLT2 inhibitors. In SELECT's acute eGFR substudy, the dip reached its lowest point around week 8 and recovered by week 20 (Colhoun et al., Nature Medicine 2024). In FLOW, long-term eGFR decline was 1.16 mL/min/1.73 m² per year slower with semaglutide. A drop larger than 30%, especially with vomiting or dehydration, is different and needs medical evaluation.
Can I take Ozempic with stage 3 CKD?
Stage 3 CKD (eGFR 30 to 59) often overlaps with the population where Ozempic injection's T2D + CKD kidney-risk indication may apply, but eGFR alone is not enough. UACR, CKD cause, diabetes status, symptoms, and other medications all factor in. FLOW used eGFR plus UACR criteria, and your clinician will use the full picture to decide whether FLOW-like evidence applies to you.
Can I take Ozempic with stage 4 CKD?
Generally yes, with careful monitoring. FLOW enrolled patients with eGFR as low as 25, and the FDA label allows use down to eGFR 15. But stage 4 is a higher-stakes situation. Your kidneys have less margin if you get dehydrated or sick. A nephrologist should be involved in the decision and the monitoring plan.
Is Wegovy kidney-protective like Ozempic?
Wegovy and Ozempic are the same molecule (semaglutide) at different doses. The SELECT trial showed Wegovy injection 2.4 mg lowered kidney composite events by 22% in adults with overweight and obesity and cardiovascular disease without diabetes (Colhoun et al., Nature Medicine 2024). But Wegovy does not have an FDA-approved kidney indication. The trial signal is real; the regulatory approval is not there yet.
Is Mounjaro or Zepbound kidney-protective?
Tirzepatide shows promising kidney signals in SURPASS-4 (T2D + high CV risk) and reduced albuminuria across the SURPASS-1 through 5 trials. A dedicated kidney outcomes trial in CKD has not read out yet, and tirzepatide does not have an FDA kidney indication. The data are encouraging but not yet at the same level as semaglutide.
Can GLP-1 drugs cause kidney damage?
The main kidney warning in FDA labels for the GLP-1 class is acute kidney injury due to volume depletion from severe GI reactions, not proven direct kidney toxicity. Severe vomiting, diarrhea, or inability to drink fluids can cause dehydration, which can cause AKI. The FDA labels for the major GLP-1 products recommend monitoring kidney function in patients with severe GI reactions (FDA Ozempic label, 2025).
What eGFR is too low for a GLP-1?
For semaglutide, liraglutide, dulaglutide, and tirzepatide, FDA labels generally do not require renal dose adjustment, and use is supported down to eGFR 15 with limited data below that. Exenatide IR is not recommended in severe renal impairment or ESRD. Exenatide ER (Bydureon BCise) is not recommended for eGFR below 45 or ESRD. Lixisenatide has limited experience in severe renal impairment and is not recommended in ESRD or eGFR below 15. Below eGFR 15 and on dialysis, evidence is very limited and decisions should be made with a nephrologist.
Should I take a GLP-1 or an SGLT2 inhibitor for my kidneys?
Current guidelines (KDIGO 2024; ADA 2026) recommend layering them in adults with T2D and CKD, along with an ACE inhibitor or ARB. They work through different mechanisms and appear complementary. The SGLT2 inhibitor class has the broadest CKD evidence across both diabetic and non-diabetic CKD. GLP-1s add cardiovascular protection, weight loss, and for Ozempic injection in T2D plus CKD, FDA-approved kidney protection on top.
What labs should I check if I am on a GLP-1 and have CKD?
Ask your doctor about eGFR (creatinine-based, and cystatin C-based if you have lost significant weight), UACR, electrolytes including potassium, blood pressure, A1c if diabetic, and any drug interactions. Exact frequency depends on CKD stage, UACR, recent medication changes, symptoms, potassium risk, and your clinician's monitoring plan.
Will Ozempic show up as kidney protection on my insurance?
For Ozempic injection 1 mg used in adults with type 2 diabetes and CKD, the FDA-approved kidney indication may be relevant to prior authorization, but coverage still depends on the plan, formulary, diagnosis documentation, step therapy, and payer rules. Outside that specific population, kidney protection is not in the approved label and is unlikely to be the basis for coverage.
Sources and last-verified date
This page was verified on May 19, 2026. Next scheduled review: August 2026. Verification covered FDA labels, primary trial publications, and current guidelines.
Primary trial sources
- ·Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109–121.
- ·Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30:2058–2066.
- ·Heerspink HJL, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes. Nat Med. October 2024.
- ·Shaman AM, et al. Effect of the GLP-1 receptor agonists semaglutide and liraglutide on kidney outcomes (pooled SUSTAIN 6 and LEADER analysis). Circulation. 2022;145(8):575–585.
- ·Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes (SURPASS-4 post-hoc). Lancet Diabetes Endocrinol. 2022;10(11):774–785.
- ·Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide (AMPLITUDE-O). N Engl J Med. 2021;385:896–907.
- ·McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SOUL). N Engl J Med. 2025.
- ·Tuttle KR, et al. Dulaglutide versus insulin glargine in moderate-to-severe CKD (AWARD-7). Lancet Diabetes Endocrinol. 2018;6(8):605–617.
- ·Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes (EXSCEL). N Engl J Med. 2017;377:1228–1239.
- ·Gerstein HC, et al. Dulaglutide and renal outcomes in T2D (REWIND). Lancet. 2019;394:131–138.
- ·Adamson C, et al. Initial Decline (Dip) in eGFR After Initiation of Dapagliflozin (DAPA-HF). Circulation. 2022.
- ·Mann JFE, et al. Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes Obes Metab. 2021;23:2058–2066.
Regulatory and guideline sources
- ·US FDA. Ozempic (semaglutide injection) prescribing information. Updated January 2025.
- ·US FDA. Prescribing information for Wegovy injection 2.4 mg, Wegovy HD injection 7.2 mg (approved March 2026), Wegovy tablets (approved December 2025), Rybelsus, Ozempic tablets, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Bydureon BCise, Adlyxin, and Foundayo (orforglipron, approved April 2026). Verified May 19, 2026.
- ·Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.
- ·American Diabetes Association. Standards of Care in Diabetes 2026, Section 11: Chronic Kidney Disease and Risk Management.
- ·National Kidney Foundation. GLP-1 Receptor Agonists. Patient education page. Verified May 19, 2026.
Not sure which path fits your situation?
Take our free 60-second matching quiz. We ask about your insurance situation, state, budget, diabetes status, and medical history, and match you to FDA-approved paths that may fit. No payment, no commitment.
Take the Free 60-Second Matching Quiz →This page is educational research. It does not diagnose conditions or recommend treatment for any individual. If your kidney function is changing or you have questions about your medications, contact your clinician. If you have severe symptoms — heavy vomiting, very low urine output, dizziness, or confusion — seek medical attention.
Published:
· Last verified: May 19, 2026.Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.